Microbot Medical Inc. (NASDAQ: MBOT) recently disclosed in a document filed with the U.S. Securities and Exchange Commission (SEC) that the company has approved a special bonus for their Chief Executive Officer, President, and Chairman, Harel Gadot. The payment, authorized on January 17, 2025, amounts to approximately $150,000.
This decision was outlined in an 8-K form submitted to the SEC on January 24, 2025. The bonus approval signifies a recognition of Gadot’s contributions to the company and his role in steering Microbot Medical towards its strategic goals.
Microbot Medical, a Delaware-based company trading on the NASDAQ Capital Market under the symbol MBOT, is dedicated to innovative medical technologies. Should there be any further developments or disclosures, investors and stakeholders will be duly informed as per regulatory requirements.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Microbot Medical’s 8K filing here.
About Microbot Medical
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Featured Stories
- Five stocks we like better than Microbot Medical
- Trading Stocks: RSI and Why it’s Useful
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Consumer Staples Stocks, Explained
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Despite Short-Term Risks Freeport McMoran Worth a Look
